Pneumotox metrics: Drugs, patterns, users and countries. Foreground and quiet zones

Camus, P.; Camus, Clio; Beltramo, Guillaume; Bonniaud, Philippe

doi:10.1183/13993003.congress-2019.oa1613

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…46 Drug-related pneumonitis is a form of lung disease that is predominant (but not exclusively) in the lung interstitium and occurs after a number of therapies. 47 The mechanisms of drug-related pneumonitis are largely unknown but may be a result of direct cytotoxic effects, oxidative stress, or immune-mediated reactions. 48,49 Pneumonitis has also been associated with many anticancer therapies, 50 including chemotherapy (pemetrexed, 51 docetaxel, 52 bleomycin, 53 and gemcitabine 54 ), targeted therapy (epidermal growth factor receptor tyrosine kinase inhibitors 55 and anaplastic lymphoma kinase inhibitors 56 ), stem-cell transplantation, 57 and chest RT.…”

Section: Characteristics Of Pneumonitis Associated With Icb Treatmentmentioning

confidence: 99%

“…29,39,41,83 Clinical conditions that can mimic IR-pneumonitis include infectious pneumonia, which may be viral, bacterial, or fungal in origin 83,84 ; infective exacerbations of chronic obstructive pulmonary disease 85 ; congestive heart failure; lymphangitic carcinomatosis; RT-pneumonitis; or the effects of systemic anticancer drugs or other agents. 45,47,86 In the setting of ICB therapy after cCRT for stage III NSCLC, the ability to differentiate IR-pneumonitis from RT-pneumonitis is of particular relevance and may present diagnostic and management challenges. RT-pneumonitis typically develops 4 to 12 weeks after completing RT and may be followed by radiation fibrosis within 6 to 12 months of completing treatment in a subset of patients.…”

Section: Diagnosing Immune-related Pneumonitismentioning

confidence: 99%

See 1 more Smart Citation

Immune-Related Pneumonitis After Chemoradiotherapy and Subsequent Immune Checkpoint Blockade in Unresectable Stage III Non–Small-Cell Lung Cancer

Naidoo

Nishino

Patel

et al. 2020

Clinical Lung Cancer

View full text Add to dashboard Cite

Approximately one third of patients with nonesmall-cell lung cancer (NSCLC) present with stage III or locally advanced NSCLC. These patients have historically been managed with chemoradiotherapy. However, outcomes for these patients remain poor, with a 5-year survival rate between 15% and 32%. Immune checkpoint inhibitors have revolutionized the treatment of patients with NSCLC. One such agent, durvalumab, a selective high-affinity human immunoglobulin G1 monoclonal antibody that blocks programmed cell death ligand 1 binding to programmed cell death protein 1 and cluster of differentiation 80, was recently approved in the consolidation setting after completion of definitive platinum-based chemoradiotherapy and has become the current standard of care for patients with stage III locally advanced NSCLC. Immune checkpoint blockade is associated with increased risk of immunotherapy-related adverse events, which can be managed most effectively when detected early, ideally in the context of a multidisciplinary approach. Pneumonitis represents the potentially most severe and life-threatening of all reported immunotherapy-related adverse events, but it is further complicated in the context of recent prior therapies also known to cause pulmonary toxicity, such as radiotherapy. However, there are major gaps in our ability to identify immunotherapy-related pneumonitis and distinguish it from radiation pneumonitis. This review aims to define the key steps in the detection, diagnosis, and treatment of immunotherapy-related pneumonitis.

show abstract

Section: Characteristics Of Pneumonitis Associated With Icb Treatmentmentioning

confidence: 99%

Section: Diagnosing Immune-related Pneumonitismentioning

confidence: 99%

Immune-Related Pneumonitis After Chemoradiotherapy and Subsequent Immune Checkpoint Blockade in Unresectable Stage III Non–Small-Cell Lung Cancer

Naidoo

Nishino

Patel

et al. 2020

Clinical Lung Cancer

View full text Add to dashboard Cite

show abstract

“…These chemical databases also typically exclude biologics. Other very comprehensive toxicity databases, such as PNEUMOTOX [17] for pulmonary toxicity and LiverTox [18] for liver toxicity, cover only a single organ system and may differ in methodologies. Machine learning models for toxicity that are trained on these datasets [19,20,21,22,23], while useful, suffer from the same limitations as the underlying datasets.…”

Section: Introductionmentioning

confidence: 99%

UniTox: Leveraging LLMs to Curate a Unified Dataset of Drug-Induced Toxicity from FDA Labels

Silberg,

Swanson,

Simon

et al. 2024

Preprint

View full text Add to dashboard Cite

Drug-induced toxicity is one of the leading reasons new drugs fail clinical trials. Machine learning models that predict drug toxicity from molecular structure could help researchers prioritize less toxic drug candidates. However, current toxicity datasets are typically small and limited to a single organ system (e.g., cardio, renal, or liver). Creating these datasets often involved time-intensive expert curation by parsing drug label documents that can exceed 100 pages per drug. Here, we introduce UniTox1, a unified dataset of 2,418 FDA-approved drugs with drug-induced toxicity summaries and ratings created by using GPT-4o to process FDA drug labels. UniTox spans eight types of toxicity: cardiotoxicity, liver toxicity, renal toxicity, pulmonary toxicity, hematological toxicity, dermatological toxicity, ototoxicity, and infertility. This is, to the best of our knowledge, the largest such systematic humanin vivodatabase by number of drugs and toxicities, and the first covering nearly all FDA-approved medications for several of these toxicities. We recruited clinicians to validate a random sample of our GPT-4o annotated toxicities, and UniTox’s toxicity ratings concord with clinician labelers 87–96% of the time. Finally, we benchmark a graph neural network trained on UniTox to demonstrate the utility of this dataset for building molecular toxicity prediction models.

show abstract

Pneumotox metrics: Drugs, patterns, users and countries. Foreground and quiet zones

Cited by 2 publications

References 0 publications

Immune-Related Pneumonitis After Chemoradiotherapy and Subsequent Immune Checkpoint Blockade in Unresectable Stage III Non–Small-Cell Lung Cancer

Immune-Related Pneumonitis After Chemoradiotherapy and Subsequent Immune Checkpoint Blockade in Unresectable Stage III Non–Small-Cell Lung Cancer

UniTox: Leveraging LLMs to Curate a Unified Dataset of Drug-Induced Toxicity from FDA Labels

Contact Info

Product

Resources

About